Introduction
Recent advances in chemotherapy for colorectal cancer (CRC) have contributed to remarkable improvements in the prognosis of this disease. Regorafenib, which is an anti-vascular endothelial growth factor (VEGF) therapy, was approved by the US Food and Drug Administration (FDA) in September 2012 for the treatment of patients with metastatic CRC who were previously treated with fluoropyrimidine-, oxaliplatin-and irinotecan-based chemotherapy [1, 2] . However, regorafenib is associated with a high incidence of adverse events such as hand-foot skin reactions and elevated liver enzymes; thus, it must be administered cautiously. On the other hand, bevacizumab is an anti-VEGF agent that reportedly causes intestinal perforation in approximately 1% of patients [3] . Despite the similar actions of regorafenib and bevacizumab on the VEGF receptor, there are few reports of intestinal perforation or Stevens-Johnson syndrome (SJS) associated with regorafenib use. Here, we report our experience with a patient who developed intestinal perforation and SJS following regorafenib administration for recurrent rectal cancer.
Abstract
Regorafenib monotherapy is useful for the treatment of colorectal cancer (CRC), which is refractory to multiple anti-cancer agents. However, it is associated with a high incidence of adverse events such as hand-foot skin reactions, elevated liver enzymes, etc. Although there are few reports of Stevens-Johnson syndrome (SJS) or intestinal perforation associated with regorafenib, such events should be taken into consideration, as with various other anti-cancer therapies, including bevacizumab. Our patient was a 61-year-old Japanese woman who underwent low anterior resection for stage IIIA rectal cancer in July 2012. Following surgery, the patient received S-1 monotherapy for 6 months. In May 2013, metastasis was observed in the peritoneal and lymph nodes. She received both oxaliplatin-and irinotecan-based chemotherapies, including bevacizumab; however, her disease continued to progress. A mutation of KRAS exon 2 precluded anti-EGFR therapy; thus, we administered regorafenib from January 2014. A whole-body, pruritic, skin rush developed on day 12 and continued to worsen. In addition, the mucosae of her palpebral conjunctiva, mouth and anus became reddish and edematous with pain on day 14. She was diagnosed with SJS based on the symptoms and high serum granulysin levels (10 ng/ml); she received steroid therapy from day 14. Severe abdominal pain developed on day 16. Computed tomography revealed free air in the abdominal cavity. Her condition worsened. Because her cancer was advanced and refractory, we could not perform surgery. She received best supportive care and died on day 65. Regorafenib is useful for refractory and metastatic CRC; however, it is associated with a high incidence of adverse events. This is the first report of intestinal perforation and SJS following regorafenib administration. Therefore, regorafenib should be carefully monitored for treatment of CRC. clinical trial registered as UMIN000003272 conducted by the Japan Clinical Oncology Group (JCOG), which was a randomized study of capecitabine vs. S-1 for stage III CRC as an adjuvant chemotherapy.
Case Report
Our patient was a 61-year-old Japanese woman who underwent low anterior resection for rectal cancer in July 2012. The pathological diagnosis was adenocarcinoma (tub2 > por2), and it was classified as T4aN1M0 p Stage III based on the criteria of the Union for International Cancer Control (7 th edition). After surgery, she received adjuvant chemotherapy with S-1(tegafur, gimeracil and oteracil potassium) for 6 months, according to the findings of the JCOG0910 Erythema multiforme seen on the breast (A) and legs (B). Oral and palpebral conjunctiva mucositis (C and D) of this patient. Systemic eruptions and mucositis developed on day 13. Individual necrotic keratinocytes (arrows) and lymphocytic infiltration of the epidermis were observedin a biopsy specimen by erythema of the left arms (E). Hematoxylin and eosin stain; ×400.
In May 2013, computed tomography revealed the recurrence of peritoneal and lymph node metastasis. As an initial treatment, the patient received six cycles of Cape-Ox + Bv and two cycles of IRIS + Bv [4, 5] . However, these treatment regimens failed and the disease progressed. Because of a mutation in KRAS exon 2, we did not administer anti-EGFR therapy but rather administered regorafenib monotherapy as a tertiary chemotherapy from January 2014. Her Eastern Cooperative Oncology Group performance status was grade 0. Laboratory data are shown in table 1. She had no history of allergy or smoking. Her medication history included esomeprazole (20 mg/ day) for gastroesophageal reflux disease and magnesium oxide (500 mg, three times perday) for constipation. On day 12 of the first cycle of regorafenib monotherapy, a pruritic skin rash developed. The skin rash worsened and the mucosae of her palpebral conjunctiva, mouth and anus became reddish and edematous with pain. She presented to our hospital on day 14 with diffuse erythema and a whole-body rash with a small part of skin detachment and bullous lesions ( Figure 1 ). Laboratory results revealed serum granulysin levels >10 ng/ml and other laboratory data were shown at table 2. She was admitted to our hospital diagnosed of SJS. Steroid pulse therapy with methylprednisolone (1000 mg/day i.v.) was started from day 14. On day 16, the patient developed abdominal pain with symptoms of peritoneal irritation. Computed tomography revealed free air in the abdominal cavity ( Figure 2 ). Although symptoms of the skin and mucous membrane tended to improve and serum granulysin levels decreased to <10 ng/ml, her condition worsened and her cancer was advanced and refractory, we could not perform surgery. Therefore, she received best supportive care and died on day 65 of the first administration of regorafenib monotherapy.
Discussion
Our patient received regorafenib for metastatic rectal cancer. However, she developed intestinal perforation and died. Such an adverse event is rare because only two cases of intestinal perforation using regorafenib have been reported to date [6] , but the FDA has indicated an association between regorafenib and gastrointestinal perforations through the action mechanism of regorafenib. However, it should be noted that our patient received corticosteroids before abdominal symptoms precipitated by intestinal perforation. It was reported that corticosteroid use is associated with increased risk of gastrointestinal bleeding and perforation, thus corticosteroid use may have caused intestinal perforation [7] . Intestinal perforation could be due to corticosteroid use, colorectal cancer metastasis and administration of regorafenib. Consequently, it is difficult to define causality with other possible factors being involved. On the other hand, SJS has been widely reported in the literature since the 1940s and is classified as a severe form of erythema multiforme [8, 9] . We arrived at a diagnosis of SJS based on the diagnostic criteria of the Ministry of Health, Labour and Welfare in Japan according to symptoms of erythema multiform with fever and involvement of the mucous membranes. There is only one report of SJS arising from regorafenib treatment [10] . The algorithm for assessment of causality in SJS and toxic epidermal necrolysis (ALDEN) score of this patient was three (unlikely). However, this novel drug induced SJS or toxic epidermal necrolysis and thus cannot affect the ALDEN score enough [11] . Her concomitant medications were esomeprazole and magnesium oxide but esomeprazole has been known as a non-significant risk of severe cutaneous adverse reactions (SCAR), and the risk of SCAR after magnesium oxide treatment has not been assessed [12] . Furthermore, in this case, Naranjo score associated with regorafenib and SJS is five (defined as a probable adverse drug reaction) [13] . Serum granulysin is useful for the diagnosis of drug-induced skin reactions occurring in SJS and toxic epidermal necrolysis [14] . Indeed there was still no consensus on treatment of SJS, in the present case, we administered steroid therapy for SJS. Before administration of regorafenib, there was no indication of SJS or intestinal perforation. Both SJS and intestinal perforation are severe adverse events; thus, it is important to identify patients at risk for SJS or intestinal perforation because of the use of anti-VEGF receptor agents. Indeed, although SJS and intestinal perforation are rare adverse events of anti-cancer drugs, they can be lethal. Therefore, the use of regorafenib as an anti-VEGF receptor agent should be carefully monitored.
